Viatris' Quarterly Earnings Preview: What You Need to Know
Viatris' Quarterly Earnings Preview: What You Need to Know.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris aims to expand access to affordable, high-quality medicines worldwide.
The healthcare titan is expected to release its Q2 2026 earnings before the market opens on Thursday, Aug. 6. Ahead of the event, analysts expect the company's EPS to be $0.62 on a diluted basis, flat from the year-ago quarter. The company has exceeded Wall Street's EPS estimates in each of its last four quarters.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
For fiscal 2026, analysts project the company's EPS to be $2.46, up 4.7% from $2.35 in fiscal 2025. Moreover, its EPS is expected to rise 8.5% year over year to $2.67 in fiscal 2027.
VTRS stock has surged 97.6% over the past 52 weeks, outperforming the S&P 500 Index's ($SPX) 19.1% rise and the State Street Healthcare Select Sector SPDR ETF's (XLV) 22.2% rise during the same time frame.
Viatris has outperformed the broader market over the past year as investors responded positively to its execution on cost-cutting initiatives, debt reduction, and portfolio optimization. The company has also benefited from improving margins, resilient cash flow, and growing contributions from higher-value products such as complex generics and biosimilars, which have helped offset pricing pressure in its traditional generic drug business.
Analysts are fairly bullish on VTRS, with the stock having a "Moderate Buy" rating overall. Among the nine analysts covering the stock, four are recommending a "Strong Buy," four suggest a "Hold," and one suggests a "Moderate Sell." VTRS' average analyst price target is $18.11, indicating a 3% upside from current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Sinergia Empresarial continuará el seguimiento de esta información sobre viatris' Quarterly Earnings Preview: What You Need to Know y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
